U1 Small Nuclear Ribonucleoprotein

A nuclear RNA-protein complex that plays a role in RNA processing. In the nucleoplasm, the U1 snRNP along with other small nuclear ribonucleoproteins (U2, U4-U6, and U5) assemble into SPLICEOSOMES that remove introns from pre-mRNA by splicing. The U1 snRNA forms base pairs with conserved sequence motifs at the 5'-splice site and recognizes both the 5'- and 3'-splice sites and may have a fundamental role in aligning the two sites for the splicing reaction.

Also Known As:

Networked: 61 relevant articles (0 outcomes, 5 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Gearing, Marla: 4 articles (01/2018 - 10/2013)
2.	Lah, James J: 4 articles (01/2018 - 10/2013)
3.	Seyfried, Nicholas T: 4 articles (01/2018 - 10/2013)
4.	Bai, Bing: 3 articles (10/2020 - 10/2013)
5.	Reed, Robin: 3 articles (12/2018 - 03/2015)
6.	Yu, Yong: 3 articles (12/2018 - 03/2015)
7.	Dammer, Eric B: 3 articles (01/2018 - 10/2013)
8.	Duong, Duc M: 3 articles (01/2018 - 10/2013)
9.	Levey, Allan I: 3 articles (01/2018 - 04/2014)
10.	Ohe, Kenji: 3 articles (01/2018 - 05/2010)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2021 - "Previous studies have shown that U1 snRNP and its components are linked to a variety of diseases, including cancer. " 01/01/2020 - "U1 snRNP regulates cancer cell migration and invasion in vitro." 01/01/2013 - "U1 snRNP-Dependent Suppression of Polyadenylation: Physiological Role and Therapeutic Opportunities in Cancer." 05/03/2022 - "As a component of the spliceosome, U1 small nuclear ribonucleoproteins (U1RNPs) play critical roles in RNA splicing, and recent studies have shown that U1RNPs could recruit long non-coding RNAs (lncRNAs) to chromatin which are involved in cancer development. " 01/01/2013 - "Here, we review the role of U1 snRNP in 3' end mRNA processing, outline the evidence that led to the recognition of its physiological, general role in inhibiting polyadenylation, and finally highlight the possibility of manipulating this U1 snRNP function for therapeutic purposes in cancer. "
2.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 11/01/1986 - "The striking similarity that we observed between the antibody pattern produced by the mice against exogenous U1 snRNP particles and that of systemic lupus erythematosus patients suggests the possibility that the anti-Sm and anti-RNP autoimmune response may be triggered by the endogenous U snRNPs rather than by a crossreacting viral or bacterial neoantigen. " 07/01/2005 - "Most components of the U1 snRNP complex are autoantigenic in systemic lupus erythematosus (SLE) and SLE overlap syndrome, which is also called mixed connective tissue disease (MCTD). " 11/01/2013 - "Differential immunoglobulin class-mediated responses to components of the U1 small nuclear ribonucleoprotein particle in systemic lupus erythematosus and mixed connective tissue disease." 03/01/2011 - "Epitope mapping of the U1 small nuclear ribonucleoprotein particle in patients with systemic lupus erythematosus and mixed connective tissue disease." 08/01/2000 - "Systemic lupus erythematosus is characterized by the presence of high titers of autoantibodies reacting with various components of the U1 small nuclear ribonucleoprotein particle (snRNP). "
3.	Connective Tissue Diseases (Connective Tissue Disease) 09/01/1997 - "The U1 snRNP complex: an autoantigen in connective tissue diseases. " 09/15/2002 - "To characterize the T cell response to a connective tissue disease-associated autoantigen, this study generated T cell clones from patients using a set of peptides encompassing the entire linear sequence of the 70-kDa subunit of U1 snRNP (U1-70kDa) small nuclear ribonucleoprotein. " 03/01/2010 - "The detection of autoantibody reactivities to individual components of the U1 snRNP particle is potentially useful for predicting the clinical course in patients with connective tissue disease and anti-U1 snRNP antibodies." 01/01/2018 - "Mixed connective tissue disease (MCTD) is a complex overlap disease with features of different autoimmune connective tissue diseases (CTDs) namely systemic sclerosis, poly/dermatomyositis and systemic lupus erythematous in patients with antibodies targeting the U1 small nuclear ribonucleoprotein particle. " 05/01/1990 - "Serum samples from patients with connective tissue disease (CTD) were characterized using a recently developed enzyme-linked immunosorbent assay for reactivity with individual specific polypeptides of U1 small nuclear ribonucleoproteins, including the U1-70-kd protein. "
4.	Spinal Muscular Atrophy (Progressive Muscular Atrophy) 01/27/2015 - "Taken together, these studies establish potentially converging disease mechanisms in ALS and spinal muscular atrophy, with ALS-causative mutants acquiring properties representing both gain (dysregulation of SMN) and loss (reduced RNA processing mediated by U1-snRNP) of function. " 12/14/2018 - "Remarkably, mutations in the ASC-1 complex are known to cause a severe form of Spinal Muscular Atrophy (SMA), and we show that an SMA-causative mutation in an ASC-1 component or an ALS-causative mutation in FUS disrupts association between the ASC-1 complex and the RNAP II/U1 snRNP machinery. "
5.	Mixed Connective Tissue Disease (MCTD) 01/01/2021 - "MCTD is associated with an elevated antibody titer to U1 small nuclear ribonucleoprotein. " 07/01/2005 - "Most components of the U1 snRNP complex are autoantigenic in systemic lupus erythematosus (SLE) and SLE overlap syndrome, which is also called mixed connective tissue disease (MCTD). " 03/01/2011 - "A total of 15 peptides were tested in a cohort of 68 patients with SLE, 29 with MCTD and 26 healthy individuals and mapped onto the U1 snRNP structure. " 01/01/1996 - "Serum reactivities towards individual U1 snRNP proteins were determined by immunoblotting in 32 patients with mixed connective tissue disease (MCTD). " 11/01/2013 - "Differential immunoglobulin class-mediated responses to components of the U1 small nuclear ribonucleoprotein particle in systemic lupus erythematosus and mixed connective tissue disease."

Related Drugs and Biologics

1.	Small Nuclear Ribonucleoproteins (snRNP)
2.	Autoantibodies
3.	Peptides (Polypeptides)
4.	Autoantigens
5.	Immunoglobulin Fragments
6.	Chromatin
7.	Proteins (Proteins, Gene)
8.	U1 Small Nuclear Ribonucleoprotein
9.	Antibodies
10.	RNA Splice Sites

Related Therapies and Procedures

1.	Therapeutics